Myasthenia Gravis Support Group
Myasthenia gravis (MG) is a neuromuscular disease leading to fluctuating muscle weakness and fatiguability. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Although myasthenia gravis may affect any voluntary muscle, muscles that control eye and eyelid movement, facial expression, and...
"Hope springs eternal ...."
As the theory is that a peptide based vaccine strategy works with autoimmune diseases in general, not just MG, the excuse that funding for a rare disease is difficult to obtain seems questionable as the reason for delay, as the company could have tried it on a less rare autoimmune disease first where funding should have been readily available.
Phase 1 studies are for safety and side effects, not to see if the vaccine actually works. Phase 2 would do that.